#ClinicalTrial #ClinicalTrialFanart

Post-discharge nurse-led rehabilitation to improve functional activity and community participation among post-stroke #Patients in Bangladesh: #Protocol for a #RCT #ClinicalTrial Date Submitted: Apr 1, 2026. Open Peer Review Period: Apr 1, 2026 - May 27, 2026.

Post-discharge nurse-led rehabilitation to improve functional activity and community participation among post-stroke #Patients in Bangladesh: #Protocol for a #RCT #ClinicalTrial (preprint) #openscience #PeerReviewMe #PlanP

angel bunny #clinicaltrial

Scientists reveal new blood pressure treatment that works when others fail A new pill called baxdrostat is showing strong results in lowering dangerously high blood pressure in people who don’t respond to standard treatments. In a large global trial, patients saw their…

"By targeting a #hormone that causes the body to retain salt and water, this #treatment could offer a much-needed solution for millions struggling with uncontrolled #hypertension.": buff.ly/uqwnZkc

via sciencedaily
#HighBloodPressure #BloodPressure #ClinicalTrial #MedicalResearch #MedSky

How Small Grants Can Bridge a Gap — and Lead to Big Changes Cures Within Reach has spent two decades supporting efforts that many philanthropists and institutions ignore. Its hard-won lessons extend well beyond medicine.

Patients just want treatments that work, whether on or off-label and on or off-patent. Thanks @chronphilanthropy.bsky.social for sharing our story. Small #ClinicalTrial grants catalyze bigger giving and patient impact. www.philanthropy.com/news/how-one...
@coefficientgiving.bsky.social @biohub.org

Plain Language Summary of a Phase 2b Randomized Controlled Trial of Ecopipam and Its 12-Month Open-Label Extension in Children and Adolescents With Tourette Syndrome
@taneuroldisord.bsky.social
@journals.sagepub.com

journals.sagepub.com/doi/10.1177/...

#clinicaltrial #medicine #openaccess

👶 Your child may qualify if they:
✔️ Have (or may have) a peanut allergy
✔️ Follow a strict peanut-free diet
✔️ Have emergency meds, including epinephrine
Help advance research for toddlers with food allergies.
👉 Check Eligibility and Learn more: comfort-toddlers-study.com
#ClinicalTrial #PeanutAllergy

It's kinda lonely on this app

#AngelMartinez #LeeSmith #ClinicalTrial #ClinicalTrialGame #ClinicalTrialFanart #Art #digitalart

Great work to Montefiore for enrolling their first patient in PrE0510! This #ClinicalTrial is a phase II study of platinum/​etoposide plus ivonescimab for extensive-stage small cell lung cancer (#SCLC). Learn more here: bit.ly/PrE0510

Kudos to Aspirus Regional Cancer Care for enrolling their first patient in PrE0510! This #ClinicalTrial is a phase II study of platinum/​etoposide plus ivonescimab for extensive-stage small cell lung cancer (#SCLC). Learn more here: bit.ly/PrE0510

A Mobile Self-Assessment and Referral Platform for Family Caregivers of Individuals With Alzheimer Disease and Related Dementias: #Protocol for a Pilot #RCT #ClinicalTrial Background: Family caregiving for individuals with Alzheimer disease and related dementias (ADRD) is characterized by increasing complexity, intensity, and demand across the disease trajectory. Formal home- and community-based services can provide knowledge, skills, and resources to enhance preparedness and self-efficacy, which may protect against adverse caregiving outcomes; however, awareness and uptake of these services remain low. As caregivers increasingly turn to the internet for information and support in their role, technology offers an opportunity to create a more seamless pipeline between assessment and service referral to match family caregivers with targeted services that meet their specific needs. Objective: The primary objective of this #Study is to evaluate the feasibility and acceptability of CarePair—a mobile self-assessment and service referral platform—among ADRD family caregivers. Secondary objectives are to assess the preliminary efficacy of CarePair in reducing stress, depressive symptoms, and anxiety, and enhancing self-efficacy among caregivers randomized to the intervention versus an attention control condition. This #Study also aims to generate preliminary effect size estimates to inform sample size calculations for a future fully powered #RCT #ClinicalTrial (RCT). Methods: This pilot RCT will evaluate the feasibility, acceptability, and preliminary efficacy of CarePair. Eighty ADRD family caregivers will be enrolled and randomized in a 1:1 ratio to the intervention (n=40) or an attention control condition (n=40). Recruitment will be facilitated by the project #Study site located in an urban metropolitan area of the United States, targeting participants who report residing in and/or being in close proximity to any of the following locations: New York City, Long Island, and Westchester County, New York; Seattle, Washington; and Los Angeles, California. Primary feasibility outcomes include recruitment, retention, and completion rates; website usability; and intervention satisfaction. Exploratory analyses will assess preliminary efficacy on stress, depressive and anxiety symptoms, and self-efficacy. Results: This trial was funded by the National Institute on Aging in September 2023 and received approval from the institutional review board of the University of Southern California on September 10, 2025. Recruitment began in September 2025 and is scheduled to conclude in May 2026, with data collection scheduled to end in August 2026. As of February 2026, 44 participants have been enrolled and 22 have completed the #Study. Conclusions: This pilot trial will offer foundational evidence regarding the feasibility and acceptability of the CarePair intervention. #Study findings will determine if “go” criteria are met to warrant the advancement to a larger-scale efficacy trial. Participant insights will also be used to guide intervention refinements and #Digital platform optimization. By offering a low-burden, caregiver-centered mobile #App, CarePair has the potential to facilitate and streamline the timely identification of needs and referral to relevant services for ADRD family caregivers. Trial Registration: ClinicalTrials.gov NCT06418971; https://clinicaltrials.gov/#Study/NCT06418971 International Registered Report Identifier (IRRID): DERR1-10.2196/90244

JMIR Res Protocols: A Mobile Self-Assessment and Referral Platform for Family Caregivers of Individuals With Alzheimer Disease and Related Dementias: #Protocol for a Pilot #RCT #ClinicalTrial

a colorful sign that says welcome april with a heart in the middle ALT: a colorful sign that says welcome april with a heart in the middle

Wythenshawe Hospital opens the EASY-AS recruitment for April #1stOfTheMonth #April2026
@mftnhs.bsky.social @leicesterctu.bsky.social
#Heart #Cardiology #RCTs #ClinicalTrial #ClinicalResearch #Health #AorticStenosis #AS #AorticValve #Asymptomatic #Expectant #Replacement #Month #Recruitment #First

📊 How can #RealWorldData strengthen cancer #ClinicalTrial design? At #AACR26, join Session MW04: Clinical Trial Design Workshop – #RealWorldEvidence in Clinical Trial Design, chaired by @eaonc.bsky.social Group Co Chair Dr. Peter O'Dwyer🗓 Apr 17 | 3–4:30 PM | Room 31 #RWE #CancerResearch

Happy Easter from the EASY-AS Central Team!
@leicesterctu.bsky.social @thebhf.bsky.social
#RCTs #ClinicalTrial #ClinicalResearch #Heart #Cardiology #AorticStenosis #AS #ValvularDisease #AorticValve #Happy #Easter #Bunny #EasterEggs #Chocolate #Card

Angel Martinez Cosplay 🐇🪽

#clinicaltrial #clinicaltrialgame #angelmartinez #angelmartinezcosplay

Motor Imagery and Action Observation in Breast #Cancer Survivors: #Protocol for a #RCT #ClinicalTrial Background: Breast #Cancer is the most common type of #Cancer in women worldwide, and its incidence is increasing. Although breast #Cancer survival is slowly increasing, related sequelae can persist after the disease has been treated. The main physical symptoms associated with breast #Cancer survival include pain, lymphedema, and associated functional limitations. Although multiple treatments are available for alleviating symptoms in breast #Cancer survivors, their effectiveness remains limited. Motor imagery (MI) and action observation (AO) therapies, which are based on the theory of motor simulation and are used in multiple fields with satisfactory results, have been proposed as alternatives for treating pain and improving mobility and strength. Objective: This #Study aims to design, implement, and evaluate the effectiveness of a program combining MI and AO therapies to improve functionality and mobility and alleviate pain and lymphedema of the affected upper limb in women who have survived breast #Cancer. Methods: A randomized controlled clinical #Study will be conducted in a sample of 108 participants who have experienced breast #Cancer and, as a result, have pain in the affected extremity, lymphedema, or loss of strength and/or mobility. The intervention group will include 54 participants managed with the MI and AO program (a combination of MI, AO, and mobility exercises), while the control group will consist of 54 women performing mobility exercises alone. Pain intensity, muscle strength, joint range, limb diameter, fear of movement, and imagery capability will be evaluated. Results: The intervention is expected to yield improvements in pain intensity, joint range, muscle strength, and symptoms associated with lymphedema, among other outcomes. The #Study was funded in December 2023. The number of participants recruited as of manuscript submission is approximately 80, and data analysis has not yet started. These results will be published in 2026. Conclusions: The implementation of an intervention based on MI and AO has the potential to positively impact female breast #Cancer survivors who face physical and psychological sequelae that interfere with their daily lives. Trial Registration: ClinicalTrials.gov NCT07067710; https://clinicaltrials.gov/#Study/NCT07067710 International Registered Report Identifier (IRRID): DERR1-10.2196/85469

JMIR Res Protocols: Motor Imagery and Action Observation in Breast #Cancer Survivors: #Protocol for a #RCT #ClinicalTrial

Clinical Evaluation of Pediatric Pulse Oximeters in South Africa: #Protocol for a Cluster #RCT #ClinicalTrial Background: The burden of children with lower respiratory infections and low blood oxygen levels (hypoxemia) is high, and outcomes are poor in low- and middle-income countries (LMICs). Pulse oximeters noninvasively measure the capillary oxyhemoglobin saturation (SpO) to identify hypoxemia, but high-quality devices designed for the unique needs of children are rarely available in primary health care clinics (PHCs) in LMICs, where children initially access care. Objective: This #Study aims to evaluate whether 2 pediatric pulse oximeters co-designed with health care workers (HCWs) in LMICs improve the correct SpO management of children in PHCs compared to a standard pulse oximeter. Methods: We are conducting a pragmatic 3-arm cluster #RCT #ClinicalTrial in the Eastern Khayelitsha, Northern, and Tygerberg areas of Cape Town, South Africa, over 18 months between 2024 and 2026. We plan to enroll 1200 children aged younger than 2 years with an acute respiratory infection from 18 PHCs randomized to implement one of 3 pulse oximeters, either 1 standard-of-care device or 2 intervention devices. HCWs in selected PHCs will administer the intervention. Our primary outcome will be “correct SpO management,” an intermediate clinical end point between device implementation and hypoxemia outcome, defined by the following three elements necessary to reduce inappropriately treated hypoxemia: (1) device adoption—HCW use of the device as evidenced by a HCW-documented SpO and pulse rate; (2) quality SpO measurement—SpO confirmed by reference device measurement within 2% SpO above or below the HCW-measured SpO; and (3) correct SpO decision-making—an appropriate referral recommendation by the HCW. A concurrent mixed methods process evaluation will explore how, why, for whom, and to what extent these devices impact the clinical management of hypoxemic children. The primary analysis will be intention-to-treat. For all primary and secondary outcomes, we will conduct pairwise comparisons between the 2 intervention arms and the control arm. Results: Data collection commenced in 2024, and results are expected from 2026 to 2027. As of December 2025, enrollment has been completed in 12 clinics. Conclusions: While there are notable challenges inherent in designing a trial to evaluate whether pulse oximeters improve HCW SpO management of children at PHCs, our #Protocol development process attempted to address all potential limitations and sources of bias to maximize the trial’s future impact. Trial Registration: ClinicalTrials.gov NCT05914324; International Registered Report Identifier (IRRID): PRR1-10.2196/82888

JMIR Res Protocols: Clinical Evaluation of Pediatric Pulse Oximeters in South Africa: #Protocol for a Cluster #RCT #ClinicalTrial

This multicenter phase 3 #ClinicalTrial demonstrated that #Socazolimab plus #Carboplatin and #Etoposide significantly improves survival in extensive-stage small cell lung cancer, offering a potent first-line immunochemotherapeutic option.

#OpenAccess: doi.org/10.1038/s413...

FICEBO recently joined the Australian Rotator Cuff Trial (ARC)! Read the full project description and watch the video on our website:
www.ficebo.com/project/arc

#clinicaltrial #research #rct

Value of Information for Clinical Trial Design: Challenges and Opportunities Value of Information has been suggested as a

Join us for the April @vicbiostat.bsky.social seminar.

A/Prof Anna Heath from SickKids Toronto will be speaking about the Value of Information for Clinical Trial Design.

Online, 23 April 9:30am AEST

www.vicbiostat.org.au/event/value-...

#clinicaltrial #valueofinformation

I made me (green hoodie) and my friends in #clinicaltrial style (with my twist on it cause I can’t not let my own style infect it lol) #clinicaltrialgame #angelmartinez #leesmith

A mobile #Health intervention promoting physical activity to reduce #Psychological distress among workers: A #RCT #ClinicalTrial Date Submitted: Mar 25, 2026. Open Peer Review Period: Mar 25, 2026 - May 20, 2026.

Reminder>> A mobile #Health intervention promoting physical activity to reduce #Psychological distress among workers: A #RCT #ClinicalTrial (preprint) #openscience #PeerReviewMe #PlanP

Development of a Collaborative Education Program for Home Care Nursing Educators’ on-the-Job Training in End-of-Life Home Care: #Protocol for a #RCT #ClinicalTrial Background: Despite the growing demand for end-of-life home care, nursing educators responsible for on-the-job training face substantial barriers, such as time and geographical constraints, which limit their access to professional development. Collaborative online training programs offer a potential solution to these challenges. Objective: This #Study aims to develop and evaluate a collaborative online training program designed to improve the educational ability of home care nursing educators in delivering effective on-the-job training for home-based end-of-life care. Methods: This parallel group, waitlist-controlled trial recruited home care nursing managers or educators from agencies with at least one home death client in the past year. We will provide this program on the internet. The intervention will comprise three online sessions, each lasting 60 minutes and held monthly, involving one lecture and two interactive case studies related to on-the-job training in end-of-life home care. This will be followed by 8 weeks of weekly educational messages via LINE, a mobile messaging #App widely used in Japan. The control group will serve as a waitlist and will receive the same intervention after the control period. The primary outcomes are participants’ attitudes, measured using the End-of-Life Nursing Education Questionnaire. Using a centralized computer-generated randomization system, 125 home care nursing managers and educators will be recruited and randomly assigned to either the intervention or control group at a ratio of 1:1. Stratification will be based on their agency’s annual home death count between November 29, 2023, and November 29, 2024. To minimize performance bias, the intervention content has been standardized before the intervention to ensure fidelity. Results: This #Study was approved by the Ethics Committee of the Graduate School of Medicine, The University of Tokyo (2024359NI-(2)) on November 15, 2024. Participant recruitment began on November 29, 2024, and closed on December 25, 2024, with 120 participants enrolled. As of February 15, 2026, the following number of surveys were completed at each time point: 106 at T0 (the intervention group:the control group; 52:54); 103 at T1 (51:52); 102 at T2 (50:52); 40 at T3 and 43 at T4 in the intervention group; and 47 at T5, 44 at T6, and 41 at T7 in the control group. Quantitative data collection was completed by January 2026, and qualitative interviews will be completed by March 2026. Primary quantitative results and integrated results are expected to be submitted for publication in 2026-2027 and 2027-2028, respectively. Conclusions: This #Protocol can address geographical and time constraints by providing flexible, online educational resources for home care nursing educators. The anticipated outcomes include enhanced on-the-job training ability among nursing educators for home-based end-of-life care. This #Study’s findings could support broader implementation of scalable training strategies in home care settings. Trial Registration: The University Hospital Medical Information Network UMIN000056165; https://center6.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000063254 International Registered Report Identifier (IRRID): DERR1-10.2196/84330

JMIR Res Protocols: Development of a Collaborative Education Program for Home Care Nursing Educators’ on-the-Job Training in End-of-Life Home Care: #Protocol for a #RCT #ClinicalTrial

Tunnel Anastomosis vs Double-Tract Jejunal Interposition Reconstruction After Proximal Gastrectomy: #Protocol for a Multicenter Prospective #RCT #ClinicalTrial Background: Tunnel anastomosis is a novel anastomotic technique for digestive tract reconstruction following proximal gastrectomy. A previous retrospective #Study by our team demonstrated its favorable antireflux effect; therefore, we hypothesize that tunnel anastomosis is noninferior to double-tract jejunal interposition reconstruction in preventing postoperative reflux esophagitis, and we will conduct this prospective #Study to further validate this assumption. Objective: In this #Study, we will prospectively compare tunnel anastomosis with the currently more prevalent double-tract jejunal interposition reconstruction technique to further validate its safety and efficacy. Methods: This is a multicenter prospective randomized controlled #Study that will enroll 240 patients who will undergo proximal gastrectomy. The #Study will be divided into 2 groups: the tunnel anastomosis group and the double-tract jejunal interposition reconstruction group, with 120 patients in each group. Patients will undergo clinical assessments and complete questionnaires preoperatively, as well as at the 3rd, 6th, and 12th months postoperatively. The primary end point is the incidence of reflux esophagitis within 1 year. The secondary end points include perioperative safety, postoperative quality of life, and postoperative nutritional status. Results: Recruitment of patients commenced in March 2022 and is scheduled to conclude in February 2027. The follow-up for all enrolled patients will be completed by February 2028. Conclusions: To our knowledge, this is the first prospective #Study on this technique, aiming to provide novel insights into the methods of digestive reconstruction following proximal gastrectomy. Trial Registration: Chinese Clinical Trial Registry ChiCTR2200057397; https://www.chictr.org.cn/showprojEN.html?proj=154418 International Registered Report Identifier (IRRID): DERR1-10.2196/82712

JMIR Res Protocols: Tunnel Anastomosis vs Double-Tract Jejunal Interposition Reconstruction After Proximal Gastrectomy: #Protocol for a Multicenter Prospective #RCT #ClinicalTrial

Learn more about clinical trials for rare disease patients in the images in this thread, and on our website at: scge.mcw.edu/patient-care... (3/3)

#PatientEducation #RareDisease #ClinicalTrial

Learn more about clinical trials for rare disease patients in the images in this thread, and on our website at: scge.mcw.edu/patient-care... (2/3)

#PatientEducation #RareDisease #ClinicalTrial

Learn more about clinical trials for rare disease patients in the images in this thread, and on our website at: scge.mcw.edu/patient-care... (1/3)

#PatientEducation #RareDisease #ClinicalTrial

Kudos to @carlehealth.bsky.social for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/pre1702-study

FirstHealth of the Carolinas-Moore Regional Hospital
is enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. More: bit.ly/pre1702-study

International multi-stakeholder consensus statement on patient, carer and public involvement to enhance clinical trial integrity The recent update of the Declaration of Helsinki has emphasized community engagement and research integrity. Patient, carer and public involvement (PCPI) throughout the research lifecycle of random...

📝 Latest Article Alert! 📝

"International multi-stakeholder consensus statement on patient, carer and public involvement to enhance clinical trial integrity"

Khalid Saeed Khan et al.

→ doi.org/10.1080/0898...

#ResearchIntegrity
#ClinicalTrial
#MedicalScience